Exercise News and Research

Latest Exercise News and Research

Underwriters exercise over-allotment option to purchase additional 968,539 shares of AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to cover over-allotments.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Worker health checks reveal 50% men at risk of developing diabetes

Over the last one year 100,000 State Government financed worker health check ups have been conducted. The results have been an eye-opener. 800 workers after their check ups have been asked to consult their physicians immediately. These check ups included measurements of blood pressure, blood cholesterol, blood sugar and waist circumference. The workers were also questioned regarding their eating, drinking and exercising habits.

1 Apr 2010

Structured and supervised exercise can prevent postnatal depression, says study

Postnatal depression (PND) or baby blues are a recognized entity with millions of mothers suffering from it in varying degrees. It affects 13% of the new mothers usually within the first 3 months after the birth of the baby.

1 Apr 2010

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

Research has found a new benefit that mothers can obtain by breast feeding – decreased risk of type 2 diabetes. Benefits of breastfeeding for the baby have been cited for a long time now. In spite of this knowledge according to The Australian Breastfeeding Association there is a definite gap in awareness regarding health benefits that this simple yet effective practice can offer.

1 Apr 2010

Maintenance of daily routines associated with reduced rate of insomnia in older adults

A study in the April 1 issue of the journal Sleep found that the maintenance of daily routines was associated with a reduced rate of insomnia and improved quality of sleep in older adults living in a retirement community.

1 Apr 2010

Tanda Professional Restore light therapy now made available for at-home use

During a press conference yesterday, doctors and experts unveiled a groundbreaking medical device using the healing properties of light therapy for pain management and improving mobility. For the first time ever, a licensed medical device that delivers clinical levels of light therapy only previously available in a doctor's office, has now been made available for at-home use.

1 Apr 2010

Personalized online resource to help Canadians achieve healthy weight loss

A Heart and Stroke Foundation survey of almost 2,000 Canadians found that 62% reported intentionally losing five or more pounds over the past five years but failed to keep the weight off. And 70% of those who were overweight or obese regained all or even more pounds after their weight-loss efforts.

1 Apr 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $20 million of shares of its Series 4 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors.

31 Mar 2010

Rebooting and reprogramming the brain

Does the brain you were born with have to be the brain you end up with? If you can improve the function of every major organ in the body, why can't you upgrade the function of your brain? Those fundamental questions were the motivation that led Kelly Howell to create Brain Sync.

31 Mar 2010

FDA accepts filing of Lux Biosciences' NDA for Luveniq and grants application priority review

Lux Biosciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the filing of the company's New Drug Application for Luveniq™ (oral voclosporin) and has granted the application priority review.

31 Mar 2010

Cambridge Heart's fourth-quarter total revenue down 20%

Cambridge Heart, Inc., today reported results for its fourth quarter and year ended December 31, 2009. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which is expected to be filed with the Securities and Exchange Commission on March 31, 2010.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Healthy hearts: Interventions needed to keep people exercising following cardiac rehabilitation programs

Researchers from the Frances Payne Bolton School of Nursing at Case Western Reserve University found that one year after 248 individuals completed a 12-week cardiac rehabilitation program following a heart attack, bypass surgery or angioplasty, only 37% exercised three times a week to keep their hearts healthy.

30 Mar 2010

Preventive health care researchers meet to outline vision for evidence-based prevention in health care

Leading preventive health care researchers, physicians and executives assembled at U.S. Preventive Medicine® Friday to outline their vision for advancing evidence-based prevention in health care.

30 Mar 2010

Few pregnant women meet physical activity guidelines set by health officials: Study

Fewer than 1 in 4 pregnant women meet physical activity guidelines set by doctors and health officials, according to a University of North Carolina at Chapel Hill study.

30 Mar 2010

Senesco Technologies signs definitive agreements with institutional and accredited investors

Senesco Technologies, Inc. has, on March 26, 2010, entered into definitive agreements with institutional and accredited investors for a private placement of up to 11,497 shares of Convertible Preferred Stock of the Company and Warrants to purchase up to 35,928,125 shares of Common Stock for a gross purchase price of approximately $11,497,000.

30 Mar 2010

Exercise News and Research

Latest Exercise News and Research

Underwriters exercise over-allotment option to purchase additional 968,539 shares of AVEO Pharmaceuticals

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Worker health checks reveal 50% men at risk of developing diabetes

Structured and supervised exercise can prevent postnatal depression, says study

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

Maintenance of daily routines associated with reduced rate of insomnia in older adults

Tanda Professional Restore light therapy now made available for at-home use

Personalized online resource to help Canadians achieve healthy weight loss

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Cell Therapeutics agrees to sell $20M of Series 4 Preferred Stock and warrants to institutional investors

Rebooting and reprogramming the brain

FDA accepts filing of Lux Biosciences' NDA for Luveniq and grants application priority review

Cambridge Heart's fourth-quarter total revenue down 20%

Patients switching to Victoza experience further reductions in A1c and weight loss

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Healthy hearts: Interventions needed to keep people exercising following cardiac rehabilitation programs

Preventive health care researchers meet to outline vision for evidence-based prevention in health care

Few pregnant women meet physical activity guidelines set by health officials: Study

Senesco Technologies signs definitive agreements with institutional and accredited investors

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exercise News and Research

Latest Exercise News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in